ExpreS2ion Biotech Holding AB (publ)

Stockholm Stock Exchange EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ) Market Capitalization on January 14, 2025: USD 5.78 M

ExpreS2ion Biotech Holding AB (publ) Market Capitalization is USD 5.78 M on January 14, 2025, a 675.67% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

ExpreS2ion Biotech Holding AB (publ) 52-week high Market Capitalization is USD 7.14 M on December 11, 2024, which is 23.49% above the current Market Capitalization.
ExpreS2ion Biotech Holding AB (publ) 52-week low Market Capitalization is USD 166.96 K on July 29, 2024, which is -97.11% below the current Market Capitalization.
ExpreS2ion Biotech Holding AB (publ) average Market Capitalization for the last 52 weeks is USD 1.30 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Stockholm Stock Exchange: EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ)

CEO	Mr. Bent U. Frandsen MSc
IPO Date	July 29, 2016
Location	Denmark
Headquarters	SCION-DTU Science Park
Employees	18
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.

Key trends

Past 5 years